Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Atara BiotherapeuticsVaxcyteAdverum BiotechnologiesAlectorImmunovant
SymbolNASDAQ:ATRANASDAQ:PCVXNASDAQ:ADVMNASDAQ:ALECNASDAQ:IMVT
Price Information
Current Price$13.64$18.47$9.22$18.11$15.52
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.41.71.51.31.8
Analysis Score3.43.53.43.54.5
Community Score2.82.92.42.43.7
Dividend Score0.00.00.00.00.0
Ownership Score0.01.71.70.80.8
Earnings & Valuation Score0.60.60.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$35.88$48.00$23.50$34.00$45.60
% Upside from Price Target163.01% upside159.88% upside154.88% upside87.74% upside193.81% upside
Trade Information
Market Cap$1.14 billion$948.53 million$902.89 million$1.44 billion$1.52 billion
Beta2.65N/A1.721.08N/A
Average Volume931,228403,634829,019630,1581,415,889
Sales & Book Value
Annual RevenueN/AN/A$250,000.00$21.22 millionN/A
Price / SalesN/AN/A3,611.5567.92N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.37 per shareN/A$2.71 per share$2.83 per share$1.45 per share
Price / BookN/AN/A3.406.40N/A
Profitability
Net Income$-290,980,000.00$-50,270,000.00$-64,490,000.00$-105,390,000.00$-66,390,000.00
EPS($5.67)N/A($1.01)($1.71)($1.54)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-757.78%N/A
Return on Equity (ROE)-94.86%N/A-32.23%-53.86%-34.80%
Return on Assets (ROA)-82.17%N/A-28.02%-31.44%-32.38%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio9.41%10.12%28.53%6.61%35.15%
Quick Ratio9.41%10.12%28.53%6.61%35.15%
Ownership Information
Institutional Ownership PercentageN/A74.08%97.41%61.50%40.21%
Insider Ownership Percentage4.30%N/A12.40%13.90%0.24%
Miscellaneous
Employees4375816717142
Shares Outstanding83.62 million51.36 million97.93 million79.58 million97.97 million
Next Earnings Date5/5/2021 (Estimated)7/5/2021 (Estimated)5/27/2021 (Estimated)5/12/2021 (Estimated)7/5/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
INVESTOR DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm - Yahoo FinanceINVESTOR DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm - Yahoo Finance
finance.yahoo.com - April 21 at 1:15 AM
Last Chance to Actively Participate: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. (IMVT) Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021 - Yahoo FinanceLast Chance to Actively Participate: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. (IMVT) Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021 - Yahoo Finance
finance.yahoo.com - April 20 at 8:14 PM
Last Chance to Actively Participate: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. (IMVT) Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021Last Chance to Actively Participate: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. (IMVT) Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
finance.yahoo.com - April 20 at 8:14 PM
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100000 to Contact the Firm - KPVI News 6DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100000 to Contact the Firm - KPVI News 6
kpvi.com - April 20 at 3:13 PM
IMVT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021 - Yahoo FinanceIMVT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021 - Yahoo Finance
finance.yahoo.com - April 20 at 3:13 PM
IMVT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021IMVT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
finance.yahoo.com - April 20 at 3:13 PM
INVESTOR DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the FirmINVESTOR DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - April 20 at 3:13 PM
IMVT Deadline Tomorrow: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action - EIN NewsIMVT Deadline Tomorrow: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action - EIN News
einnews.com - April 20 at 10:12 AM
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Yahoo FinanceDEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Yahoo Finance
finance.yahoo.com - April 20 at 10:12 AM
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmDEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - April 20 at 10:12 AM
APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc. - Salamanca PressAPRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc. - Salamanca Press
salamancapress.com - April 20 at 5:11 AM
SHAREHOLDER DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the FirmSHAREHOLDER DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - April 19 at 5:37 PM
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Yahoo FinanceDEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Yahoo Finance
finance.yahoo.com - April 19 at 12:36 PM
IMVT Deadline Tomorrow: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021 - Yahoo FinanceIMVT Deadline Tomorrow: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021 - Yahoo Finance
finance.yahoo.com - April 19 at 12:36 PM
FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm - Yahoo Finance AustraliaFINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm - Yahoo Finance Australia
finance.yahoo.com - April 19 at 1:03 AM
FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the FirmFINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - April 19 at 1:03 AM
IMVT Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021 - Yahoo FinanceIMVT Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021 - Yahoo Finance
finance.yahoo.com - April 18 at 2:33 PM
IMVT Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021IMVT Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
finance.yahoo.com - April 18 at 2:33 PM
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Yahoo FinanceTUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Yahoo Finance
finance.yahoo.com - April 16 at 2:25 PM
SHAREHOLDER ALERT: Holzer & Holzer Encourages Immunovant Investors With Significant Losses to Contact the Firm - Yahoo FinanceSHAREHOLDER ALERT: Holzer & Holzer Encourages Immunovant Investors With Significant Losses to Contact the Firm - Yahoo Finance
finance.yahoo.com - April 16 at 2:25 PM
IMVT Tuesday Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021 - Yahoo FinanceIMVT Tuesday Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021 - Yahoo Finance
finance.yahoo.com - April 16 at 2:25 PM
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmTUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - April 16 at 2:25 PM
IMVT Tuesday Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021IMVT Tuesday Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
finance.yahoo.com - April 16 at 2:25 PM
SHAREHOLDER ALERT: Holzer & Holzer Encourages Immunovant Investors With Significant Losses to Contact the FirmSHAREHOLDER ALERT: Holzer & Holzer Encourages Immunovant Investors With Significant Losses to Contact the Firm
finance.yahoo.com - April 16 at 2:25 PM
APRIL 20 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm - Yahoo FinanceAPRIL 20 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm - Yahoo Finance
finance.yahoo.com - April 16 at 9:25 AM
3 Health Care Stocks That Could Double by Year End (IMVT)3 Health Care Stocks That Could Double by Year End (IMVT)
marketbeat.com - February 11 at 10:50 AM
DateCompanyBrokerageAction
3/2/2021Atara BiotherapeuticsWilliam BlairReiterated Rating
3/2/2021Atara BiotherapeuticsCitigroupUpgrade
12/9/2020Atara BiotherapeuticsSmith Barney CitigroupDowngrade
12/9/2020Atara BiotherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngrade
12/8/2020Atara BiotherapeuticsHC WainwrightReiterated Rating
12/7/2020Atara BiotherapeuticsStifel NicolausBoost Price Target
11/23/2020Atara BiotherapeuticsMizuhoBoost Price Target
9/14/2020Atara BiotherapeuticsCanaccord GenuityBoost Price Target
6/30/2020Atara BiotherapeuticsEvercore ISIInitiated Coverage
5/12/2020Atara BiotherapeuticsJPMorgan Chase & Co.Boost Price Target
12/10/2019Atara BiotherapeuticsCowenReiterated Rating
8/14/2020VaxcyteNeedham & Company LLCReiterated Rating
7/7/2020VaxcyteBank of AmericaInitiated Coverage
7/7/2020VaxcyteJefferies Financial GroupInitiated Coverage
7/7/2020VaxcyteCantor FitzgeraldInitiated Coverage
12/15/2020Adverum BiotechnologiesUBS GroupInitiated Coverage
11/12/2020Adverum BiotechnologiesRaymond JamesUpgrade
11/5/2020Adverum BiotechnologiesLifesci CapitalReiterated Rating
8/11/2020Adverum BiotechnologiesSVB LeerinkBoost Price Target
8/10/2020Adverum BiotechnologiesPiper SandlerBoost Price Target
6/16/2020Adverum BiotechnologiesRoyal Bank of CanadaBoost Price Target
5/30/2020Adverum BiotechnologiesChardan CapitalReiterated Rating
5/5/2020Adverum BiotechnologiesSunTrust BanksUpgrade
4/28/2020Adverum BiotechnologiesThe Goldman Sachs GroupInitiated Coverage
1/13/2020Adverum BiotechnologiesPiper Jaffray CompaniesBoost Price Target
4/19/2021AlectorMorgan StanleyBoost Price Target
7/29/2020AlectorBarclaysLower Price Target
11/27/2019AlectorBTIG ResearchInitiated Coverage
2/2/2021ImmunovantCredit Suisse GroupDowngrade
11/13/2020ImmunovantTruistBoost Price Target
11/13/2020ImmunovantRobert W. BairdBoost Price Target
10/12/2020ImmunovantGuggenheimInitiated Coverage
10/2/2020ImmunovantCSFBInitiated Coverage
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.